^
    Back
    Association details:
    Biomarker:IL7R mutation
    Cancer:B Acute Lymphoblastic Leukemia
    Drug Class:Sphingosine kinase inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    EHA 2021
    Title:

    IL7R MUTATIONAL ACTIVATION CAN INITIATE PH-LIKE AND PAX5 P80R PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

    Published date:
    05/12/2021
    Excerpt:
    We demonstrate that 2 distinct new generation sphingosine kinase inhibitors are effective against mutant IL7R mouse B-ALLs both in vitro and in vivo.